Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Recruiting

Phase 1

Phase 2

Peripheral Blood LymphocytesAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03745326

Conditions

Gastrointestinal Cancer

Pancreatic Cancer

Gastric Cancer

Colon Cancer

Rectal Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Fludarabine

Aldesleukin

anti-KRAS G12D mTCR PBL

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-25.